At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Bilastinedrug
Likely dose
Bilastine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria
In Brief
A Phase 2 clinical trial evaluating Bilastine for Allergic Rhinoconjunctivitis and Chronic Urticaria. Completed, enrolled 36 participants across 7 sites in 3 countries.
Detailed Summary
The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population subset.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinoconjunctivitis, Chronic Urticaria
CountriesAustralia, Germany, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedMar 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedMar 5, 2010
Enrollment StartJan 1, 2010
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.3 years ago
Interventions
Bilastinedrug
10 mg/qd/ 7 days.Oral dispersible tablets